![]() During the first year, 305 patients with a hemorrhagic stroke (23.0%) died, whereas 210 in the traumatic ICH group (19.3%) died. Of these events, 1325 were attributable to hemorrhagic stroke and 1090 were secondary to trauma. A total of 2415 patients with AF in this cohort (1481 men and 934 women mean age, 77.1 years ) sustained an ICH event. One-year observed event rates per 100 person-years were calculated, and treatment strategies were compared using time-dependent Cox proportional hazards regression models with adjustment for age, sex, length of hospital stay, comorbidities, and concomitant medication use. No oral anticoagulant treatment or resumption of warfarin treatment, included as a time-dependent exposure. ![]() Resumption of warfarin treatment was evaluated after hospital discharge. This nationwide observational cohort study included patients with AF who sustained an incident ICH event during warfarin treatment from January 1, 1998, through February 28, 2016. To investigate the prognosis associated with resuming warfarin treatment stratified by the type of ICH ( hemorrhagic stroke or traumatic ICH). A thrombotic risk is present however, a risk for serious harm associated with resumption of anticoagulation therapy also exists. The increase in the risk for bleeding associated with antithrombotic therapy causes a dilemma in patients with atrial fibrillation (AF) who sustain an intracranial hemorrhage (ICH). Nielsen, Peter Brønnum Larsen, Torben Bjerregaard Skjøth, Flemming Lip, Gregory Y H Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. ABSTRACT The acute management of patients on warfarin SUPPLEMENTARY NOTES International Journal of Emergency Medicine 2011 14. TITLE AND SUBTITLE Treatments For Reversing Warfarin. Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review.DATE 2. Treatments for Reversing Warfarin Anticoagulation in Patients with Acute Intracranial Hemorrhage: A Structured Literature ReviewĪvailable soon. Therefore, anticoagulation management should focus on maintaining INRs in the 2.0 to 3.0 range, even in elderly patients with atrial fibrillation, rather than International normalized ratios less than 2.0 were not associated with lower risk for intracranial hemorrhage compared with INRs between 2.0 and 3.0. The risk for intracranial hemorrhage increases at age 85 years. Although duration of anticoagulation has been associated with hemorrhage in other studies, the current study could not control for this potential confounder. The risk for intracranial hemorrhage at INRs less than 2.0 did not differ statistically from the risk at INRs of 2.0 to 3.0 (adjusted odds ratio, 1.3 ). The risk for intracranial hemorrhage increased at 85 years of age or older (adjusted odds ratio, 2.5 referent age, 70 to 74 years) and at an INR range of 3.5 to 3.9 (adjusted odds ratio, 4.6 referent INR, 2.0 to 3.0). 75 years P < 0.001) and had higher median INRs (2.7 vs. Case-patients were older than controls (median age, 78 years vs. The authors performed multivariable conditional logistic regression to determine the odds of intracranial hemorrhage with regard to age and international normalized ratio (INR), controlling for comorbid conditions and aspirin use. 170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not both case-patients and controls were taking warfarin for atrial fibrillation. To examine the relationship of age, anticoagulation intensity, and risk for intracranial hemorrhage. Optimal use of warfarin for atrial fibrillation requires precise information on the risk for intracranial hemorrhage as a function of patient age and anticoagulation intensity. However, higher intensities increase hemorrhage risk. The risk for atrial fibrillation-associated stroke increases at low anticoagulation intensities. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.įang, Margaret C Chang, Yuchiao Hylek, Elaine M Rosand, Jonathan Greenberg, Steven M Go, Alan S Singer, Daniel E
0 Comments
Leave a Reply. |